Reported about 21 hours ago
Leading vaccine manufacturers are currently optimistic about their development pipelines for 2025, despite anticipated cuts in research funding by the Trump administration. Executives from major companies like Pfizer, Moderna, and Sanofi believe the long-term need for vaccines will persist and view the funding reductions as a temporary challenge. They emphasize that their ongoing vaccine projects remain unaffected, and they are exploring new markets, such as adult vaccines and treatments for conditions like acne.
Source: YAHOO